These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23900581)

  • 21. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
    Lee S; Yoon CY; Byun SS; Lee E; Lee SE
    J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells.
    Gopalakrishnan A; Xu CJ; Nair SS; Chen C; Hebbar V; Kong AN
    Arch Pharm Res; 2006 Aug; 29(8):633-44. PubMed ID: 16964758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
    Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
    Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
    Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
    Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines.
    Sau A; Filomeni G; Pezzola S; D'Aguanno S; Tregno FP; Urbani A; Serra M; Pasello M; Picci P; Federici G; Caccuri AM
    Mol Biosyst; 2012 Apr; 8(4):994-1006. PubMed ID: 22068640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.
    Echevarría-Vargas IM; Valiyeva F; Vivas-Mejía PE
    PLoS One; 2014; 9(5):e97094. PubMed ID: 24865582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
    Su L; Wang Y; Xiao M; Lin Y; Yu L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of androgen receptor expression by Z-isochaihulactone mediated by the JNK signaling pathway and might be related to cytotoxicity in prostate cancer.
    Liu PY; Lin SZ; Sheu JJ; Lin CT; Lin PC; Chou YW; Huang MH; Chiou TW; Harn HJ
    Prostate; 2013 Apr; 73(5):531-41. PubMed ID: 23038474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effects of the novel quinazolinone MJ-33: inhibition of metastasis through the MAPK, AKT, NF-κB and AP-1 signaling pathways in DU145 human prostate cancer cells.
    Hour MJ; Tsai SC; Wu HC; Lin MW; Chung JG; Wu JB; Chiang JH; Tsuzuki M; Yang JS
    Int J Oncol; 2012 Oct; 41(4):1513-9. PubMed ID: 22825655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
    Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
    Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells.
    Kim M; Murakami A; Kawabata K; Ohigashi H
    Carcinogenesis; 2005 Sep; 26(9):1553-62. PubMed ID: 15860507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.
    Okada M; Shibuya K; Sato A; Seino S; Watanabe E; Suzuki S; Seino M; Kitanaka C
    Oncol Rep; 2013 Oct; 30(4):1957-64. PubMed ID: 23912840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
    Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. c-Jun N-terminal kinase/c-Jun inhibits fibroblast proliferation by negatively regulating the levels of stathmin/oncoprotein 18.
    Yeap YY; Ng IH; Badrian B; Nguyen TV; Yip YY; Dhillon AS; Mutsaers SE; Silke J; Bogoyevitch MA; Ng DC
    Biochem J; 2010 Sep; 430(2):345-54. PubMed ID: 20594188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines.
    Mukhopadhyay A; Bueso-Ramos C; Chatterjee D; Pantazis P; Aggarwal BB
    Oncogene; 2001 Nov; 20(52):7597-609. PubMed ID: 11753638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
    Seino M; Okada M; Sakaki H; Takeda H; Watarai H; Suzuki S; Seino S; Kuramoto K; Ohta T; Nagase S; Kurachi H; Kitanaka C
    Oncol Rep; 2016 Jan; 35(1):593-601. PubMed ID: 26534836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance.
    Jia Y; Zhang W; Liu H; Peng L; Yang Z; Lou J
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):377-85. PubMed ID: 21833590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
    Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P
    Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.